4D Molecular Therapeutics Inc (NASDAQ: FDMT) kicked off on Monday, down -5.78% from the previous trading day, before settling in for the closing price of $8.83. Over the past 52 weeks, FDMT has traded in a range of $7.32-$36.25.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 111.29%. While this was happening, its average annual earnings per share was recorded -12.05%. With a float of $43.91 million, this company’s outstanding shares have now reached $51.97 million.
Let’s determine the extent of company efficiency that accounts for 147 employees. In terms of profitability, gross margin is -53142.86%, operating margin of -1202685.71%, and the pretax margin is -1024857.14%.
4D Molecular Therapeutics Inc (FDMT) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of 4D Molecular Therapeutics Inc is 15.52%, while institutional ownership is 100.24%. The most recent insider transaction that took place on Sep 16 ’24, was worth 8,165. In this transaction Chief Legal Officer of this company sold 500 shares at a rate of $16.33, taking the stock ownership to the 6,781 shares. Before that another transaction happened on Aug 19 ’24, when Company’s Chief Legal Officer sold 500 for $15.00, making the entire transaction worth $7,500. This insider now owns 6,781 shares in total.
4D Molecular Therapeutics Inc (FDMT) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around -12.05% per share during the next fiscal year.
4D Molecular Therapeutics Inc (NASDAQ: FDMT) Trading Performance Indicators
Take a look at 4D Molecular Therapeutics Inc’s (FDMT) current performance indicators. Last quarter, stock had a quick ratio of 17.33. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 19.26.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.73, a number that is poised to hit -0.85 in the next quarter and is forecasted to reach -3.46 in one year’s time.
Technical Analysis of 4D Molecular Therapeutics Inc (FDMT)
Looking closely at 4D Molecular Therapeutics Inc (NASDAQ: FDMT), its last 5-days average volume was 1.25 million, which is a jump from its year-to-date volume of 0.9 million. As of the previous 9 days, the stock’s Stochastic %D was 62.01%. Additionally, its Average True Range was 0.58.
During the past 100 days, 4D Molecular Therapeutics Inc’s (FDMT) raw stochastic average was set at 4.63%, which indicates a significant decrease from 53.77% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 56.72% in the past 14 days, which was lower than the 97.23% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $10.17, while its 200-day Moving Average is $20.37. However, in the short run, 4D Molecular Therapeutics Inc’s stock first resistance to watch stands at $8.94. Second resistance stands at $9.56. The third major resistance level sits at $9.93. If the price goes on to break the first support level at $7.94, it is likely to go to the next support level at $7.57. Should the price break the second support level, the third support level stands at $6.95.
4D Molecular Therapeutics Inc (NASDAQ: FDMT) Key Stats
The company with the Market Capitalisation of 423.46 million has total of 46,228K Shares Outstanding. Its annual sales at the moment are 20,720 K in contrast with the sum of -100,840 K annual income. Company’s last quarter sales were recorded 10 K and last quarter income was -34,950 K.
